News

Latest News
Sep 27, 2019

Mylan N.V. (NASDAQ: MYL) today announced that it has finalized a previously disclosed civil settlement with the U.S. Securities and Exchange Commission ("SEC"). On July 29, 2019, the Company...

Sep 17, 2019

Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, a generic version of AstraZeneca's Faslodex®...

Jul 29, 2019

Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business,...

Jul 29, 2019

Mylan's Board of Directors today shared the following statement regarding Heather Bresch's retirement, which will be effective upon the closing of the combination of Mylan and Upjohn, a division...

Jul 29, 2019

Mylan N.V. (NASDAQ: MYL) today announced its financial results for the three and six months ended June 30, 2019. Second Quarter 2019 Financial Highlights U.S. GAAP diluted loss per ordinary share...

View More

Search News Releases
Contact Mylan Communications

Global Communications 
724.514.1968
communications@mylan.com

Stay Connected

Mylan: Seeing is Believing

You are leaving Mylan.com

By clicking Continue below you are leaving Mylan.com and going to a third-party site.